Tarveda Therapeutics, Inc.

Leila Alland

Rajesh R Shinde

Mark T Bilodeau

Rossitza Gueorguieva Alargova

Benoît Moreau

Brian H White

Richard Wooster

Patrick Lim Soo

Kerry Whalen

Beata Sweryda-Krawiec

Mary Simcox

Christopher Sears

Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

HSP90-targeting conjugates and formulations thereof

Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

SSTR-targeted conjugates and particles and formulations thereof

Growing community of inventors

Bernardsville, NJ, United States of America

Leila Alland